Lerochol is a novel cholesterol-lowering biologic developed to address unmet needs in the management of hypercholesterolemia. It is indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) levels in adults, including those with heterozygous familial hypercholesterolemia (HeFH).

It is designed to target PCSK9-mediated pathways, thereby enhancing LDL receptor recycling and improving the clearance of LDL-C from the bloodstream. With its innovative molecular design and extended activity profile, Lerochol offers a promising therapeutic option for patients who require additional LDL-C reduction beyond standard lipid-lowering therapies.

This makes Lerochol particularly relevant for patients at high cardiovascular risk who struggle to achieve target cholesterol levels through lifestyle modifications and conventional treatments alone.